Inhibitory effect of oral WEB 2086, a novel selective PAF-acether antagonist, on ex vivo platelet aggregation

No abstract is available for this paper.

• Publication year

  2004

• Venue

  European Journal of Clinical Pharmacology

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1007/BF00558259PMID 3181277
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Platelet-activating factor in bronchoalveolar lavage fluid from asthmatic subjects.

  1990cited by this paper
• Randomised double-blind placebo-controlled trial of feverfew in migraine prevention.

  1988cited by this paper
• Pharmacology of PAF antagonists.

  1988cited by this paper
• Effect of a Paf antagonist, WEB 2086, on airway microvascular leakage in the guinea‐pig and platelet aggregation in man

  1988cited by this paper
• Interference by the novel PAF-acether antagonist WEB 2086 with the bronchopulmonary responses to PAF-acether and to active and passive anaphylactic shock in guinea-pigs.

  1987cited by this paper
• WEB 2086. A potent PAF antagonist exerts protective effect toward PAF-induced gastric damage.

  1987cited by this paper
• A role for platelet activating factor and platelets in the induction of bronchial hyperreactivity.

  1987cited by this paper
• Pharmacological actions of WEB 2086, a new specific antagonist of platelet activating factor.

  1987cited by this paper
• Platelet-activating factor in late asthmatic response.

  1987cited by this paper
• Effect of a ginkgolide mixture (BN 52063) in antagonising skin and platelet responses to platelet activating factor in man.

  1987cited by this paper
• Antigenic release of paf-acether and beta-glucuronidase from alveolar macrophages of asthmatics.

  1987cited by this paper
• Protective effect of WEB 2086, a novel antagonist of platelet activating factor, in endotoxin shock.

  1987cited by this paper
• Platelet-activating factor mediates hemodynamic changes and lung injury in endotoxin-treated rats.

  1987cited by this paper
• Effects of WEB 2086, a novel antagonist of platelet activating factor, in active and passive anaphylaxis.

  1987cited by this paper
• A role for platelet activating factor and platelets in the induction of bronchial hyperreactivity.

  1987cited by this paper
• Triazolodiazepines: dissociation of their Paf (platelet activating factor) antagonistic and CNS activity

  1987cited by this paper
• Renal transplantation in Saudi Arabia.

  1986cited by this paper
• Effects of inhaled platelet activating factor on pulmonary function and bronchial responsiveness in man.

  1986cited by this paper
• Accumulation of eosinophils in response to intracutaneous PAF-acether and allergens in man.

  1986cited by this paper
• Cervical carcinoma in younger patients.

  1983cited by this paper
• Letter: Infant feeds and softened water.

  1975cited by this paper
• The aggregation of blood platelets

  1963cited by this paper

• Chapter 52 – Mediator Antagonists

  2009cites this paper
• Biologically Active Thiophene Derivatives Revisited: 1983–1988

  2008cites this paper
• Inhibition of ex-vivo PAF-induced platelet aggregation by the PAF-antagonist RP 48740: relationship to plasma concentrations in healthy volunteers

  2004cites this paper
• Chapter 53 – Mediator Antagonists

  2002cites this paper
• The Effect of Intravenous Administration of Web 2086 on PAF-Induced Platelet Aggregation in Healthy Friesian Calves

  1997cites this paper
• Effect of a potent platelet-activating factor antagonist, WEB-2086, on asthma. A multicenter, double-blind placebo-controlled study in Japan.

  1996cites this paper
• Synthesis and antiaggregational activity relative to platelets of the analog of platelet activating factor — 2-acetoxybenzoic acid derivative

  1995cites this paper
• Effects of the platelet‐activating factor receptor antagonist WEB 2086 on whole blood coagulation and fibrinolysis in a thromboelastography assay

  1995cites this paper
• The effect of the orally active platelet-activating factor antagonist WEB 2086 in the treatment of asthma.

  1994cites this paper
• Clinical experience with platelet-activating factor antagonists. Past, present, and near future.

  1994cites this paper
• Effect of a specific platelet-activating factor antagonist on cardiovascular and peripheral cellular responses to colonic ischemia and reperfusion in anesthetized ponies.

  1993cites this paper
• Cardiovascular responses to exogenous platelet-activating factor (PAF) in anesthetized ponies, and the effects of a PAF antagonist, WEB 2086.

  1993cites this paper
• Phospholipids and their inhibitors: A critical evaluation of their role in the treatment of sepsis

  1992cites this paper
• Thieno-triazolo-1,4-diazepines as antagonists of platelet-activating factor: Present status

  1991cites this paper
• Inhibition of cutaneous and platelet responses to platelet-activating factor by oral WEB 2086 in man.

  1991cites this paper
• Platelet Activating Factor and Asthma

  1991cites this paper
• Biochemical pharmacology of platelet-activating factor (and PAF antagonists) in relation to clinical and experimental thrombocytopenia.

  1991cites this paper
• Pharmacodynamics, pharmacokinetics and safety profile of the new platelet-activating factor antagonist apafant in man.

  1991cites this paper
• Effects of the synthetic ether phospholipid KO-286011 on cells and components of rabbit blood.

  1991cites this paper
• The Involvement of Paf in Thrombotic Events

  1991cites this paper
• Inhibitory effects of the new PAF acether antagonist WEB‐2086 on pharmacologic changes induced by PAF inhalation in human beings

  1990cites this paper
• Pharmacologic activity of bepafant (WEB 2170), a new and selective hetrazepinoic antagonist of platelet activating factor.

  1990cites this paper
• Preclinical and clinical pharmacology of platelet‐activating factor receptor antagonists

  1990cites this paper
• [Platelet activating factor--a biologically active phospholipid].

  1990cites this paper
• Failure of the platelet-activating-factor antagonist WEB 2086 BS for treatment of chronic autoimmune thrombocytopenia

  1990cites this paper
• A triazolodiazepine platelet activating factor receptor antagonist (WEB 2086) reduces pulmonary dysfunction during endotoxin shock in swine.

  1990cites this paper
• PAF-induced platelet aggregation ex vivo as a method for monitoring pharmacological activity in healthy volunteers.

  1989cites this paper
• Hetrazepines as antagonists of platelet activating factor

  1989cites this paper
• Safety, tolerability., and pharmacologic activity of multiple doses of the new platelet activating factor antagonist WEB 2086 in human subjects

  1989cites this paper
• The interplay between platelet and vessel-wall mediators in coronary artery occlusion.

  1989cites this paper
• Idiopathic thrombocytopenia treated with Paf-acether antagonist WEB 2086.

  1988cites this paper